bsrbr-ra uk crn id: 7302 july 2014 update. recruitment certolizumab must have diagnosis of ra must...
TRANSCRIPT
BSRBR-RAUK CRN ID: 7302
July 2014 update
Recruitment Certolizumab
Must have diagnosis of
RA
Must be registered within 6 months of first dose of certolizumab
Can be re-registered if already on the
study
TocilizumabMust have
diagnosis of RA
Must be registered within 6 months of first
dose of IV or S/C tocilizumab
Can be re-registered if already on the
study
Anti-TNF Comparison CohortMust have
diagnosis of RA
Must be registered within 6 months of first dose of etanercept, adalimumab or infliximab
Numbers recruited up to 30/06/2014
854As of 30/06/2014
956As of 30/06/2014
720As of 30/06/2014
Recruitment over the last year
Certolizumab recruitment by month (1 July 2013 – 30 June 2014)
Tocilizumab recruitment by month (1 July 2013 – 30 June 2014)
Anti-TNF cohort recruitment by month (1 July 2013 – 30 June 2014)
Jul-13
Aug-13
Sep-13
Oct-13
Nov-13
Dec-13
Jan-14
Feb-14
Mar-14
Apr-14
May-14
Jun-1405
10152025303540
3531
12 13Number recruitedTrendline
Jul-13
Aug-13
Sep-13
Oct-13
Nov-13
Dec-13
Jan-14
Feb-14
Mar-14
Apr-14
May-14
Jun-140
102030405060
4250
26
39
25 Number recruitedTrendline
Jul-13
Aug-13
Sep-13
Oct-13
Nov-13
Dec-13
Jan-14
Feb-14
Mar-14
Apr-14
May-14
Jun-1405
1015202530
2328
12
26
Number recruitedTrendline
Recruitment 01/01/2014 – 30/06/2014
BSR Region Awards January 2014 – July 2014
North West East
of England
West Midlands
69 56 50
East Midlands
Recent BSRBR-RA publications– Risk of solid cancer in patients exposed to anti-TNF therapy: results from the
BSRBR-RA. Mercer, L., Lunt, M., Low, A., Dixon, W., Watson, K., Symmons, D. &Hyrich, K (2014). Ann Rheum Dis, [Epub ahead of print]
- Biologic treatment response among adults with juvenile idiopathic arthritis: results from the British Society for Rheumatology Biologics Register.
McErlane F, Foster HE, Davies R, Lunt M, Watson KD, Symmons DP, Hyrich KL. (2013) Rheumatology (Oxford), [Epub ahead of print]
– The risk of gastrointestinal perforations in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the BSRBR-RA. Závada, J., Lunt, M., Davies, R., Low, A., Mercer, L., Galloway, J., Watson, K., Symmons, D., Hyrich, K. & (2013). Ann Rheum Dis, [Epub ahead of print]
Accessing BSRBR-RA data• You can access data from the BSRBR-RA via a “third party data request form” (contact [email protected] for a copy).
• Proposals should be discussed with [email protected]@manchester.ac.ukin advance of submission to discuss feasibility.
•Proposals can be submitted at any time of the year – there are no submission deadlines.
http://www.rheumatology.org.uk/resources/bsr_biologics_registers/
Recent/ongoing research projects via the BSRBR-RA data access scheme
Non-inflammatory pain mechanisms as confounders in the clinical assessment of synovitis in RA
Study of fatigue in inflammatory arthritis
Effectiveness of TNF response define by season of initiation of therapy, with particular focus on vitamin D
To explore the influence of gender and gender-related variables on severity of prognosis for RA
Obesity and clinical response to anti-TNF medication
Contacts
Email: [email protected]
Tel: 0161 275 1652/7390
Web: http://man.ac.uk/mS3HTm
Twitter: @BSRBR_RA
Acknowledgements
• UK Consultant Rheumatologists and Specialist Nurses
• UK Comprehensive Research Networks
• BSRBR-RA Control Centre Consortium
• British Society for Rheumatology
• Arthritis Research UK Centre for Epidemiology, Manchester